| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
Apogee Therapeutics, Inc.$133.65
+0.07 (+0.05%)
C 40Pipeline Score Richly Valued Biotech · Clinical
Market Cap
6.11 B
EPS
-4.33
P/E Ratio
-
Value Trade
93.75 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
60.82 M
Operating CF
-55.57 M
Total Assets
1.29 B
Total Liabilities
37.86 M
D/E Ratio
12,345
-2.09 %
Week
-12.31 %
1 Month
18.4 %
3 Month
28.36 %
6 Month
277.49 %
5 Year
277.49 %
All Time
Cash Data
Cash Position
1.06 B
Monthly Burn
18.52 M
Runway
55.4 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
787.82 K
52 Week Range
34.34 - 95.32
% held by Insiders
24.3 %
% held by Institutions
75.49 %
Enterprise Value
5.06 B
Total Shares
61.90 M
Short %
10.57 %
Float Shares
48.84 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Apogee Therapeutics, Inc.
154Total events
9Upcoming
51Tier-1 (high impact)
2023 – 2029Coverage
Upcoming catalysts 9
Event history 145
Q3 2026
◆Topline ReadoutAPG279Clinical Data
Phase 1b readout expected
moderate-to-severe atopic dermatitissource ↗
Q3 2026
◆Trial InitiationzumilokibartTrial
Initiation of Phase 2a ELEVATE trial in EoE
eosinophilic esophagitissource ↗
Jun 22, 2026
▲Primary Endpoint MetzumilokibartClinical Data
Phase 2 trial of zumilokibart met primary endpoint with significant skin clearance at 16 weeks
atopic dermatitissource ↗
Jun 22, 2026
▲Long Term DatazumilokibartClinical Data
Longer-term data from Phase 2 trial supports quarterly or twice-yearly maintenance dosing
atopic dermatitissource ↗
Jun 22, 2026
▲Full ResultsAPG333Clinical Data
Phase 1 data for APG333 showed long half-life and suppression of type 2 inflammatory markers for up to six months
asthmasource ↗
Jun 22, 2026
▲Interim AnalysiszumilokibartTrial
Positive interim results from Phase 1b study of zumilokibart in asthma
asthmasource ↗
Jun 10, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat
Jun 3, 2026
May 27, 2026
▲Partnership / LicensezumilokibartCorporate
Strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion
atopic dermatitissource ↗
Drug Pipeline Intelligence
C40
Pipeline Score $486M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 58%
Small Cap (rank 384 of 911)
Percentile RankApogee Therapeutics, Inc. carries a moderate pipeline score (40/100), with $748M risk-adjusted pipeline value, led by APG777 in Atopic Dermatitis (Phase 2), across $52B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APG777 Small molecule | Atopic Dermatitis | Phase 2 | NCT07027527 | 17% | $748M | ACTIVE NOT_RECRUITING | 906 | FAST | C (52) | Dec 1, 2027 | MODERATE_RISK | LOW Jun 8, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
zumilokibart | moderate-to-severe atopic dermatitis | Phase 2 | 2026-05-27 | EASI 75: 65.9% of patients treated with mid-dose zumilokibart achieving EASI-75 (41.9% placebo adjusted) Read More | Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis Read More | |
zumilokibart | moderate-to-severe atopic dermatitis | Phase 2 | 2026-05-27 | EASI 75: 65.9% of patients treated with mid-dose zumilokibart achieving EASI-75 (41.9% placebo adjusted) Read More | Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis Read More | |
zumilokibart | moderate-to-severe atopic dermatitis | Phase 2 | 2026-05-27 | EASI 75: 65.9% of patients treated with mid-dose zumilokibart achieving EASI-75 (41.9% placebo adjusted) Read More | Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in APGE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
APGE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
APGE▲ +46.7%on this news
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie has announced its acquisition of Apogee Therapeutics for approximately $10.9 billion, enhancing its immunology portfolio. The deal includes Apogee's lead asset, zumilokibart, a monoclonal antibody for atopic dermatitis, and other promising candidates targeting inflammatory diseases. The acquisition is expected to close in Q3 2026, pending regulatory and shareholder approvals.
Read more →APGE▲ +5.6%on this news
Apogee Therapeutics to Participate in Upcoming June 2026 Conferences
Apogee Therapeutics, Inc. (Nasdaq: APGE) announced its participation in two upcoming investor conferences in June 2026. The Jefferies Global Healthcare Conference will be held on June 3, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10. Live and archived webcasts of the events will be available on their website.
Read more →APGEApogee Therapeutics to Participate in Upcoming June Conferences
Apogee Therapeutics announced its participation in two upcoming investor conferences in June 2026. The Jefferies Global Healthcare Conference is scheduled for June 3, and the Goldman Sachs 47th Annual Global Healthcare Conference will take place on June 10. The company aims to highlight its innovative biologics and pipeline targeting various inflammatory and immune indications.
Read more →APGE▼ -6.1%on this newsshared move
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
Apogee Therapeutics has announced a strategic financing collaboration with Blackstone Life Sciences, securing up to $1.3 billion to advance the Phase 3 development and commercialization of its drug, zumilokibart. This funding includes synthetic royalty and senior corporate debt, allowing Apogee to maintain a self-sustainable financial profile. The partnership is expected to significantly impact the treatment landscape for moderate-to-severe atopic dermatitis.
Read more →APGE▼ -6.1%on this newsshared move
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
Apogee Therapeutics has announced positive results from Part B of the Phase 2 APEX trial for zumilokibart, an anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis. The trial met all primary and secondary endpoints, showing significant efficacy and a favorable safety profile. The company plans to advance zumilokibart into Phase 3 trials in the second half of 2026.
Read more →APGEApogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
Read more →APGEApogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
Apogee Therapeutics has reported significant progress in its pipeline, particularly with zumilokibart for atopic dermatitis (AD), showing durable efficacy in Phase 2 trials. The company has a strong cash position of $1.3 billion, allowing for continued development and planned BLA filing for AD. Upcoming milestones include Phase 3 trials for AD and further details on asthma and eosinophilic esophagitis (EoE) studies.
Read more →APGEApogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
Apogee Therapeutics, Inc. has successfully closed its public offering, raising approximately $403 million. The offering included 5,750,000 shares, with the underwriters fully exercising their option to purchase additional shares. The funds will be utilized to advance Apogee's clinical-stage biologics targeting various inflammatory and immunology indications.
Read more →APGE▲ +7.6%on this newsshared move
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
Apogee Therapeutics, Inc. has announced the pricing of its public offering, selling 5 million shares at $70 each, aiming to raise approximately $350 million. The offering is set to close on March 26, 2026, pending customary conditions. The funds will support Apogee's development of novel biologics in the inflammatory and immunology markets.
Read more →APGE▼ -7.9%on this newsshared move
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
Apogee Therapeutics, Inc. has announced a proposed underwritten public offering of $300 million in common stock, with an option for underwriters to purchase an additional $45 million. The funds will support preclinical studies, clinical trials, and other corporate activities. The offering is contingent on market conditions, and details will be provided in a prospectus.
Read more →APGE▲ +20%on this newsshared move
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
Apogee Therapeutics will report 52-week data from the Phase 2 APEX trial of zumilokibart for moderate-to-severe atopic dermatitis on March 23, 2026. Following the announcement, a conference call and webcast will be held to discuss the results. The company focuses on developing novel biologics for various inflammatory and immunology conditions.
Read more →APGE▲ +20%on this newsshared move
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis A
Apogee Therapeutics announced encouraging 52-week outcomes from Part A of the Phase 2 APEX trial for its drug, zumilokibart (APG777), targeting moderate-to-severe atopic dermatitis. The results highlight durable maintenance of treatment responses with 3- and 6-month dosing regimens. The company aims to initiate Phase 3 trials within the year, potentially leading to a commercial launch by 2029, suggesting a promising future for the treatment landscape in atopic dermatitis.
Read more →APGEApogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
Apogee Therapeutics has reported significant progress in its pipeline, particularly with zumilokibart for atopic dermatitis, with key trial data expected soon. The company anticipates initiating Phase 3 trials by the end of 2026 and has a robust cash position to support its operations into 2028. Additionally, positive interim results from asthma trials suggest potential for broader applications of its therapies.
Read more →APGEApogee Therapeutics to Participate in Upcoming March Conferences
Apogee Therapeutics announced its participation in several upcoming conferences, including the TD Cowen 46th Annual Health Care Conference and the UBS Biotech Summit Miami. The management will engage in a fireside chat and attend additional events to discuss the company's advancements in treating inflammatory and immune conditions. This participation highlights Apogee's commitment to its innovative pipeline.
Read more →APGEApogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
Apogee Therapeutics announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, scheduled for February 12, 2026. The company's management will engage in a fireside chat, which will be available via a live and archived webcast. Apogee is focused on developing novel biologics for various inflammatory and immunological conditions.
Read more →APGEApogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
Apogee Therapeutics will host a conference call on January 6, 2026, to report interim results from its Phase 1b trial of APG777 for mild-to-moderate asthma. The live webcast will start at 8:00 a.m. ET, allowing investors and stakeholders to access the findings. The company aims to address significant unmet needs in the inflammatory and immunology markets.
Read more →APGEApogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticip
Apogee Therapeutics announced positive interim results from its Phase 1b trial of zumilokibart (APG777), demonstrating significant FeNO suppression in patients with mild-to-moderate asthma. The results emphasize the drug's potential as a foundational therapy for Type 2 inflammatory diseases. With a robust cash position to support its development plans, Apogee's pipeline includes significant upcoming milestones for both asthma and atopic dermatitis through 2026. The company anticipates advancing zumilokibart towards a potential market launch in 2029.
Read more →APGEApogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Apogee Therapeutics reported significant pipeline advancements and third quarter 2025 financial results, highlighting four anticipated clinical data readouts in 2026. The interim results for APG333 showed promising outcomes, supporting potential extended dosing schedules. The company completed a $345 million public offering, ensuring financial stability through 2028. CEO Michael Henderson emphasized the company's readiness for transformative developments in the coming year.
Read more →APGEApogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
Apogee Therapeutics announced positive interim Phase 1 results for APG333, a novel TSLP antibody. The trial showed a half-life of about 55 days and effective biomarker suppression for up to six months after a single dose. The results indicate potential for less frequent dosing, enhancing treatment options for respiratory diseases. APG333 was well tolerated in healthy volunteers.
Read more →APGEApogee Therapeutics to Participate in Upcoming Conferences
Apogee Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including the Guggenheim Healthcare Innovation Conference and the Stifel Healthcare Conference. These events will feature management in fireside chats discussing the company's innovative therapies. Apogee aims to highlight its advancements in treating conditions like Atopic Dermatitis and asthma.
Read more →APGEApogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
Apogee Therapeutics, Inc. has successfully closed a public offering of 8,048,782 shares, raising approximately $345 million. The offering included the full exercise of underwriters' options for additional shares. The company aims to advance its innovative biologics targeting major inflammatory and immunology markets. This funding will support the development of their lead program, APG777, for Atopic Dermatitis.
Read more →APGE▲ +12.6%on this newsshared move
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
Apogee Therapeutics, Inc. has announced the pricing of its underwritten public offering, totaling approximately $300 million. The offering includes nearly 7 million shares of common stock priced at $41.00 each, along with pre-funded warrants. The offering is expected to close on October 10, 2025, pending customary closing conditions.
Read more →APGE▲ +12.6%on this newsshared move
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
Apogee Therapeutics, Inc. has announced a proposed underwritten public offering of its common stock, which may include pre-funded warrants. The proceeds will support preclinical studies, clinical trials, and other corporate activities. The offering's completion is uncertain and subject to market conditions. Jefferies and other firms are managing the offering.
Read more →APGEApogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
Apogee Therapeutics announced that data from the Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis will be presented at the EADV Congress 2025. The trial's 16-week results demonstrated that APG777 met its primary and secondary endpoints, reinforcing its potential as a leading treatment option. The company will also showcase additional findings related to its combination therapy strategies.
Read more →APGEApogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
Apogee Therapeutics will participate in the Stifel 2025 Virtual Immunology and Inflammation Forum on September 16, 2025. The management will engage in a fireside chat, which will be accessible via a webcast. The company focuses on developing novel biologics for various immunology and inflammation conditions, including Atopic Dermatitis and asthma.
Read more →APGEApogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Read more →APGEAPOGEE THERAPEUTICS, INC. CONDENSED CONSOLIDA TED STATEMENT OF OPERATIONS (UNAUDITED) (In thousands) THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2025 2024 2025 2024 Operating expenses: Research and development
Apogee Therapeutics, Inc. reported progress in its clinical pipeline and second quarter 2025 financial results. The Phase 2 APEX trial for APG777 showed positive outcomes, meeting primary endpoints with the potential for less frequent dosing compared to standard care. The company maintains a strong cash position of $621.2 million, expected to fund operations into early 2028. Additionally, enrollment in the APEX Phase 2 Part B trial has accelerated, and a Phase 1b head-to-head trial of a new combination therapy is underway. Overall, Apogee is advancing its innovative treatments in the competitive space of inflammatory and immunology diseases.
Read more →APGE▼ -17.3%on this news
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
Apogee Therapeutics announced positive results from the Phase 2 APEX trial of APG777, showing a 66.9% EASI-75 response rate in patients with moderate-to-severe atopic dermatitis at Week 16. The trial met all primary and secondary endpoints, indicating strong efficacy and a favorable safety profile. Further studies, including APEX Part B, are planned to optimize dosing and assess long-term effects.
Read more →APGE▼ -17.3%on this newsshared move
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Read more →APGEApogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
Read more →APGE▲ +6.1%on this news
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mi
Apogee Therapeutics has provided a business update discussing advancements in its pipeline and first quarter 2025 financial results. The Phase 2 APEX trial of APG777 for atopic dermatitis is progressing, with interim results expected in mid-2025. Additionally, the company has initiated a Phase 1b trial of APG777 for asthma, with positive interim results from another asthma medication, APG808. The company remains financially healthy, with significant funds supporting its operations until early 2028.
Read more →APGE▲ +6.1%on this news
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
Read more →APGEApogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
Read more →APGEApogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Read more →APGEApogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedul
Apogee Therapeutics reported substantial progress in its pipeline and financial results for the full year 2024, with a focus on the ongoing Phase 2 APEX clinical trial for APG777. The company achieved over-enrollment in Part A and has initiated Part B ahead of schedule, with key results expected mid-2025. Additionally, encouraging interim results from a Phase 1 trial of APG990 support the development of a combination therapy, APG279, with a readout expected in the second half of 2026. Apogee's strong cash position of $731.1 million is projected to sustain operations into 2028, despite ongoing net losses.
Read more →APGEApogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
Read more →APGEApogee Therapeutics to Participate in Upcoming March Investor Conferences
Apogee Therapeutics to Participate in Upcoming March Investor Conferences
Read more →APGEApogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis Enrollment of Part A completed ahead of schedule and exceeded enrollment t
Apogee Therapeutics announced that the first patient has been dosed in Part B of the Phase 2 APEX trial for APG777 in treating moderate-to-severe atopic dermatitis. Enrollment for Part A was completed ahead of schedule, exceeding the target of 110 patients with 123 enrolled. The trial is designed to streamline the evaluation process and aims to provide proof-of-concept data in mid-2025. Additionally, Apogee plans to explore further development of APG777 for other inflammatory and immunology conditions.
Read more →APGEApogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
Read more →APGEApogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions Interim safety and pharma
Apogee Therapeutics has commenced dosing participants in a Phase 1 clinical trial of its novel half-life extended TSLP antibody, APG333, aimed at treating respiratory conditions such as asthma and COPD. This trial marks an important advancement in the company's pipeline, following successful preclinical proof-of-concept for a combination therapy with APG777. The study is designed to assess the safety, tolerability, and pharmacokinetics of APG333 in healthy volunteers, with interim results expected in the second half of 2025. Apogee aims to leverage this investigational therapy in a combination approach to address various inflammatory and immunological conditions.
Read more →APGEApogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of
Apogee Therapeutics reported significant advancements during its inaugural R&D Day, highlighting the promising interim Phase 1 data for its novel biologic programs APG808 and APG777 targeting inflammatory and immunology diseases. APG808 demonstrated a half-life of approximately 55 days while APG777 showed a best-in-class potential with a 77-day half-life. The company plans to accelerate the APG777 Phase 2 trial in atopic dermatitis due to strong enrollment and has also outlined plans for combination therapies aimed at improving treatment efficacy. Apogee aims to address underserved markets with its pipeline of innovative therapies.
Read more →APGEApogee Therapeutics Announces Agenda for Virtual R&D Day
Apogee Therapeutics Announces Agenda for Virtual R&D Day
Read more →APGEApogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Read more →APGE▼ -5.1%on this news· ran to -22% by day 3
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continu
Apogee Therapeutics reported strong progress across its pipeline, particularly with APG777, which is expected to enter Phase 2 trials in 2025. The company has $754 million in cash, allowing it to sustain its operations until 2028. Upcoming milestones include interim data from the Phase 1 trials for APG808 and APG990. However, there was a notable increase in net loss due to rising R&D and G&A expenses.
Read more →APGEApogee Therapeutics to Participate in Upcoming November Investor Conferences
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
Read more →APGEApogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases Pharmacokinetic d
Apogee Therapeutics announced positive results from the Phase 1 trial of APG777, a half-life extended anti-IL-13 antibody. The trial data showed promising pharmacokinetic and pharmacodynamic results, including a half-life of approximately 75 days and significant inhibition of inflammation markers. Continuing development, Apogee expects to provide proof-of-concept data from the ongoing Phase 2 trial for atopic dermatitis in the second half of 2025, aiming for better dosing frequency and patient adherence compared to current therapies.
Read more →APGEApogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
Read more →APGEApogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
Read more →APGEApogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
Read more →APGE▲ +10.6%on this news
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases Interim safet
Apogee Therapeutics, Inc. has initiated the first phase 1 clinical trial for APG990, a novel OX40L antibody targeting atopic dermatitis and other inflammatory diseases. The trial will assess safety, tolerability, and pharmacokinetics in approximately 40 healthy volunteers, with interim results anticipated in 2025. Additionally, a phase 1 trial combining APG990 and APG777 is planned to evaluate its potential for enhanced efficacy in treating inflammation. The company's approach aims to address unmet needs in the inflammatory and immunology markets.
Read more →APGE▲ +9.8%on this news
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data
Apogee Therapeutics reported significant progress in its pipeline and financial results for the second quarter of 2024. The company is focusing on its lead candidates, including APG777 and APG990, with anticipated clinical milestones in 2025. Apogee aims to deliver innovative therapies targeting major inflammatory and immunological diseases, driven by a robust financial position expected to last into 2028 despite current operating losses. Their strategy includes exploring combination therapies to maximize treatment efficacy in various respiratory conditions.
Read more →APGEApogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD San Francisco, CA and Waltham, MA
Apogee Therapeutics has appointed Dr. Lisa Bollinger to its board of directors, adding her extensive regulatory and clinical experience to the team. Dr. Bollinger previously held leadership roles at Merck and Amgen, contributing to her suitability for Apogee, especially as the company prepares for significant milestones in 2024. Apogee is focused on developing biologics for conditions with high unmet needs such as atopic dermatitis and COPD. The company believes that its innovative approaches could deliver meaningful benefits over current treatments.
Read more →APGEApogee Therapeutics to Participate in Upcoming June Investor Conferences
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
Read more →APGEApogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases In
Apogee Therapeutics has initiated dosing of the first patient in its Phase 2 clinical trial for APG777, an innovative anti-IL-13 antibody designed for treating moderate-to-severe atopic dermatitis. The trial was prompted by favorable results from a prior Phase 1 study, which demonstrated a promising pharmacokinetic profile and patient safety. With 16-week proof-of-concept data expected in the second half of 2025, the company plans to explore further indications, including asthma. This trial combines typical Phase 2a and 2b phases, potentially expediting development timelines.
Read more →APGEApogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in pa
Apogee Therapeutics announced significant advancements in its pipeline, including the initiation of a Phase 2 clinical trial for APG777 aimed at treating moderate-to-severe atopic dermatitis. The company also reported financial results for the first quarter of 2024, highlighting a substantial public offering that raised $483 million, ensuring operational funding until 2028. In addition, interim data from ongoing trials of APG808 for COPD is expected in the second half of 2024. There remains investor concern regarding net losses amidst ambitious development goals.
Read more →APGEApogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
Read more →APGE▼ -5%on this news
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4R Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Dise
Apogee Therapeutics has initiated the dosing of healthy volunteers in a Phase 1 clinical trial for APG808, an extended half-life monoclonal antibody aimed at treating moderate-to-severe chronic obstructive pulmonary disease (COPD) and other inflammatory diseases. This trial follows positive results from another candidate, APG777. The company anticipates interim safety and pharmacokinetic data from the trial in the second half of 2024, and is planning further development of APG808 based on the outcomes. Apogee's focus is on optimizing biologics to improve treatment options for patients with inflammatory and immunological conditions.
Read more →APGEApogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million
Read more →APGEApogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
Read more →APGE▲ +42.1%on this news· ran to +62% by day 3shared move
APG777 PHASE 1 DATA March 2024 © Apogee Therapeutics, Inc. 2 Disclaimers and Forward-looking statements This presentation contains certain "forward-looking statements" within the meaning of applicable securities law
Apogee Therapeutics, Inc. has announced the anticipated initiation of the Phase 1 trial for APG808 in the first half of 2024, which aims to assess its safety and pharmacokinetics. The data suggests that APG808 could outperform Dupixent, especially in terms of potential extended half-life and lower variability in patient responses. The program also aims to explore the efficacy of OX40L treatment in various inflammatory conditions, hinting at a deeper clinical effect for a wider patient subset. This progress positions Apogee as a potential leader in a competitive therapeutic area.
Read more →APGE▲ +42.1%on this news· ran to +62% by day 3shared move
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
Read more →APGE▲ +42.1%on this news· ran to +62% by day 3shared move
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approx
Apogee Therapeutics announced positive interim results from its Phase 1 clinical trial of APG777, indicating a favorable safety profile and pharmacokinetics. The company reported a significant cash position of $395.5 million, expected to support operations into the fourth quarter of 2026. Furthermore, Apogee plans to initiate a Phase 2 trial for APG777 in patients with moderate-to-severe atopic dermatitis ahead of schedule. However, the company reported a net loss of $31.7 million for the most recent quarter, reflecting increased operational costs.
Read more →APGE▲ +12.1%on this news· ran to +75% by day 3shared move
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
Read more →APGEApogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Read more →APGE▲ +7.3%on this news
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule
Apogee Therapeutics has reported progress in its clinical development programs, specifically the Phase 1 trial of APG777, which is targeting atopic dermatitis. The trial began ahead of schedule, with safety and pharmacokinetic data expected by mid-2024. The company also announced the nomination of APG808 as a development candidate, aimed at IL-4R with a focus on multiple allergic diseases. Furthermore, Apogee remains financially robust, with substantial cash reserves that support their ongoing operations through 2026.
Read more →APGEApogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
Read more →APGEApogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
Read more →APGEApogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results $345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical trial init
Apogee Therapeutics, a clinical-stage biotech company, reported strong corporate progress and financial results for Q2 2023, raising $345 million in an upsized IPO intended to support operations into Q4 2026. The company has initiated a Phase 1 clinical trial for its lead product candidate, APG777, ahead of schedule. Notably, Apogee aims to develop innovative therapies for atopic dermatitis, COPD, and other inflammatory diseases. The management elaborated on their pipeline of monoclonal antibodies designed to improve therapy standards.
Read more →APGEApogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board San Francisco, CA and Waltham, MA
Apogee Therapeutics has appointed Mark C. McKenna, a veteran in the healthcare industry, as the new Chairman of its Board. Mr. McKenna brings extensive experience from his previous roles, notably as the CEO of Prometheus Biosciences, which was acquired by Merck for $10.8 billion. His leadership is expected to enhance Apogee's strategic direction and support the company's efforts in advancing biologics for inflammatory and immunology indications. The appointment occurs as Apogee aims to leverage its strong financial position and innovative pipeline.
Read more →APGEApogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases Preclinical
Apogee Therapeutics has initiated the dosing of healthy volunteers in its Phase 1 trial for APG777, a novel anti-IL-13 antibody intended for treating atopic dermatitis and other inflammatory diseases. The dosing began ahead of schedule, marking a significant milestone for the company as it transitions into the clinical stage. APG777 aims to improve upon existing treatments by offering a longer half-life, which could enable patients to receive injections every two to three months rather than more frequently. Initial safety and pharmacokinetic data are expected in mid-2024, paving the way for a planned Phase 2 trial later next year.
Read more →APGEApogee Therapeutics to Participate in Upcoming August Investor Conferences
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
Read more →APGEApogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Read more →APGEApogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering
Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering
Read more →APGEApogee Therapeutics Launches with $169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders
Apogee Therapeutics Launches with $169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders
Read more →Competitive Position
How APGE ranks across every disease it competes inCompetitive Position is a premium feature
See how APGE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial